feed,title,long_url,short_url
Investing,Gold and Silver See Long Sentiment Cool Even as Prices Climb,https://www.investing.com/analysis/gold-and-silver-see-long-sentiment-cool-even-as-prices-climb-200672165,
Investing,Bubbles Are Everywhere You Look,https://www.investing.com/analysis/bubbles-are-everywhere-you-look-200672164,
Investing,S&P 500 E-Mini: Next Move Hinges on Follow-Through Near Key Averages,https://www.investing.com/analysis/sp-500-emini-next-move-hinges-on-followthrough-near-key-averages-200672163,
Investing,"Santa’s Shiny Ornaments: Gold, Silver and Platinum Extend a Run That Few Expected",https://www.investing.com/analysis/santas-shiny-ornaments-gold-silver-and-platinum-extend-a-run-that-few-expected-200672169,
Investing,Crude Oil: US–Venezuela Tensions Put a Geopolitical Floor Under Prices,https://www.investing.com/analysis/crude-oil-usvenezuela-tensions-put-a-geopolitical-floor-under-prices-200672167,
Investing,Silver Extends Uptrend After Clearing Key Resistance Zones,https://www.investing.com/analysis/silver-extends-uptrend-after-clearing-key-resistance-zones-200672162,
Investing,"Harbour Energy to acquire LLOG for $3.2 billion, enters US Gulf",https://www.investing.com/news/stock-market-news/harbour-energy-to-acquire-llog-for-32-billion-enters-us-gulf-4418512,
Investing,Rank Group reports payment fraud in Spanish operations,https://www.investing.com/news/stock-market-news/rank-group-reports-payment-fraud-in-spanish-operations-93CH-4418510,
Investing,GSK agrees to lower drug prices for Americans in deal with US government,https://www.investing.com/news/stock-market-news/gsk-agrees-to-lower-drug-prices-for-americans-in-deal-with-us-government-4418508,
Investing,Defence Holdings advances with first customer contract for Project Ixian,https://www.investing.com/news/stock-market-news/defence-holdings-advances-with-first-customer-contract-for-project-ixian-93CH-4418493,
Investing,BofA says near-term risk of forced selling by CTAs remains limited,https://www.investing.com/news/stock-market-news/bofa-says-nearterm-risk-of-forced-selling-by-ctas-remains-limited-4418492,
Investing,AstraZeneca’s ceralasertib fails to meet primary endpoint in lung cancer trial,https://www.investing.com/news/stock-market-news/astrazenecas-ceralasertib-fails-to-meet-primary-endpoint-in-lung-cancer-trial-93CH-4418486,
